Immunological foundations to the quest for new vaccine adjuvants

BioDrugs

Volumn 18, Issue 2, 2004, Pages 79-93

  Burdin, Nicolas ^a   Guy, Bruno ^a   Moingeon, Philippe ^a,b  

^a SANOFI PASTEUR   (France)

^b Stallergenes SA   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM SALT; BACTERIAL TOXIN; CALCIUM PHOSPHATE; CHOLERA VACCINE; FLT3 LIGAND; FREUND ADJUVANT; GUANINE DERIVATIVE; HEAT LABILE TOXIN; IMMUNOLOGICAL ADJUVANT; LIPID; LIPOSOME; MONTANIDE; OLIGONUCLEOTIDE; OM; PERTUSSIS TOXIN; PHOSPHORYL LIPID A; POLYCYTOSINE GUANINE; POLYGLACTIN; PROTEIN B7.1; RC 529; RECOMBINANT CYTOKINE; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; SAPONIN DERIVATIVE; SQUALENE; UNCLASSIFIED DRUG; VACCINE; VIROSOME;

ANTIGEN PRESENTING CELL; B LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL TRIAL; DRUG DESIGN; DRUG RESEARCH; DRUG SCREENING; DRUG TARGETING; HUMAN; HUMORAL IMMUNITY; IMMUNE SYSTEM; IMMUNITY; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION; INFLAMMATION; LYMPHOCYTE ACTIVATION; MALIGNANT NEOPLASTIC DISEASE; MEMORY CELL; MICROORGANISM DETECTION; MUCOSA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; T LYMPHOCYTE; VACCINE PRODUCTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODY FORMATION; CHEMISTRY, PHARMACEUTICAL; DRUG DESIGN; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC MEMORY; MEMBRANE GLYCOPROTEINS; MUCOUS MEMBRANE; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTORS; VACCINES;

EID: 1942505745     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200418020-00002     Document Type: Review

References (100)

1. Schijns V. Immunological concepts of vaccine adjuvant activity. Curr Opin Immunol 2000; 12: 456-63
2. Vogel FR. Improving vaccine performance with adjuvants. Clin Infect Dis 2000; 30 Suppl. 3: S266-70
3. Moingeon P, Haensler J, Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine 2001; 19: 4363-72
4. Moingeon P. Strategies for designing vaccines eliciting Th1 responses in humans. J Biotechnol 2002; 98: 189-98
5. Czerkinsky C, Anjuere F, McGhee J, et al. Mucosal immunity and tolerance: relevance to vaccine development Immunol Rev 1999; 170: 197-222
6. Hunter RL. Overview of vaccine adjuvants: present and future. Vaccine 2002; 20 Suppl. 3: S7-12
7. Engers H, Kieny MP, Malhotra P, et al. Third meeting on novel adjuvants currently in or close to clinical testing. Vaccine 2003; 81: 3503-24
8. Persing DH, Coler RN, Lacy MJ, et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends Microbiol 2002; 10 (10 Suppl.): S32-7
9. Aguado T, Engers H, Pang T, et al. Novel adjuvants currently in clinical testing: November 2-4 1998, Fondation Mérieux, Annecy, France. A meeting sponsored by the World Health Organization. Vaccine 1999; 17: 2321-8
10. Saul A, Lawrence G, Smillie A, et al. Human phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide ISA720 adjuvant. Vaccine 1999; 17: 3145-59
11. Evans TG, Hasan M, Galibert L, et al. The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults. Vaccine 2002; 21: 322-9
12. Moingeon P, De Taisne C, Almond J. Delivery technologies for human vaccines. Br Med Bull 2002; 62: 29-44
13. Edelman R. The development and use of vaccine adjuvants. Mol Biotechnol 2002; 21 (2): 129-48
14. Aujame L, Burdin N, Vicani M. How microarrays can improve our understanding of immune responses and vaccine development. Ann N Y Acad Sci 2002; 975: 1-23
15. Berzofsky JA, Ahlers JD, Belyakov IM. Strategies for designing and optimizing new generation vaccines. Nat Rev Immunol 2001; 1 (3): 209-19
16. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003; 21: 335-76
17. Janeway Jr CA, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216
18. Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-7
19. Sallusto F, Schaerli P, Loetscher P, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol 1998; 28: 2760-9
20. Sozzani L, Sallusto F, Luini W, et al. Migration of dendritic cells in response to formyl peptides, C5a, and a distinct set of chemokines. J Immunol 1995; 155 (7): 3292-5
21. Biragyn A, Tani K, Grimm M, et al. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999; 17: 253-8
22. Sallusto F, Lanzavecchia A, Mackay CR. Chemokines and chemokine receptors in T-cell priming and Th1/Th2-mediated responses. Immunol Today 1998; 19 (12): 568-74
23. Martin MU, Wesche H. Summary and comparison of the signaling mechanisms of the Toll/interleukin-1 receptor family. Biochim Biophys Acta 2002; 1592 (3): 265-80
24. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002; 20: 709-30
25. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002; 3 (2): 196-200
26. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens. J Exp Med 2001; 194: 863-9
27. Ronaghy A, Prakken BJ, Takabayashi K, et al. Immunostimulatory DNA sequences influence the course of adjuvant arthritis. J Immunol 2002; 168 (1): 51-6
28. Schwartz DA, Quinn TJ, Thorne PS, et al. CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. J Clin Invest 1997; 100 (1): 68-73
29. Bendelac A, Bonneville M, Kearney JF. Autoreactivity by design: innate B and T lymphocytes. Nat Rev Immunol 2001; 1 (3): 177-86
30. Kronenberg M, Gapin L. The unconventional lifestyle of NKT cells. Nat Rev Immunol 2002; 2 (8): 557-68
31. Burdin N, Kronenberg M. CD1-mediated immune responses to glycolipids. Curr Opin Immunol 1999; 11 (3): 326-31
32. Gonzalez-Aseguinolaza G, Van Kaer L, Bergmann CC, et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002; 195 (5): 617-24
33. Hayakawa Y, Takeda K, Yagita H, et al. Differential regulation of Th1 and Th2 functions of NKT cells by CD28 and CD40 costimulatory pathways. J Immunol 2001; 166 (10): 6012-8
34. Giaccone G, Punt CJ, Ando Y, et al. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin Cancer Res 2002; 8 (12): 3702-9
35. Ferrarini M, Ferrero E, Dagna L, et al. Human gamma delta T cells: a nonredundant system in the immune-surveillance against cancer. Trends Immunol 2002; 23 (1): 14-8
36. Carding SR, Egan PJ. Gamma delta T cells: functional plasticity and heterogeneity. Nat Rev Immunol 2002; 2 (5): 336-45
37. Sireci G, Espinosa E, Di Sano C, et al. Differential activation of human gamma delta cells by nonpeptide phosphoantigens. Eur J Immunol 2001; 31 (5): 1628-35
38. Espinosa E, Belmant C, Pont F, et al. Chemical synthesis and biological activity of bromohydrin pyrophosphate, a potent stimulator of human gamma delta T cells. J Biol Chem 2001; 276 (21): 18337-44
39. Kaech SM, Wherry EJ, Ahmed R. Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol 2002; 2 (4): 251-62
40. Lanzavecchia A, Sallusto F. Progressive differentiation and selection of the fittest in the immune response. Nat Rev Immunol 2002; 2 (12): 982-7
41. Lanzavecchia A, Sallusto F. Antigen decoding by T lymphocytes: from synapses to fate determination. Nat Immunol 2001; 2 (6): 487-92
42. Hunter CA, Reiner SL. Cytokines and T cells in host defense. Curr Opin Immunol 2000; 12 (4): 413-8
43. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 2003; 300 (5617): 339-42
44. Sprent J, Surh CD. Generation and maintenance of memory T cells. Curr Opin Immunol 2001; 13 (2): 248-54
45. Badovinac VP, Tvinnereim AR, Harty JT. Regulation of antigen-specific CD8+ T cell homeostasis by perforin and interferon-gamma. Science 2000; 290 (5495): 1354-8
46. Badovinac VP, Porter BB, Harty JT. Programmed contraction of CD8 (+) T cells after infection. Nat Immunol 2002; 3 (7): 619-26
47. Westermann J, Ehlers EM, Exton MS, et al. Migration of naive, effector and memory T cells: implications for the regulation of immune responses. Immunol Rev 2001; 184: 20-37
48. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8 T cell subsets. Nat Immunol 2003; 4 (3): 225-34
49. Kaech SM, Hemby S, Kersh E, et al. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002; 111 (6): 837-51
50. Opferman JT, Ober BT, Ashton-Rickardt PG. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science 1999; 283 (5408): 1745-8
51. Ochsenbein AF, Karrer U, Klenerman P, et al. A comparison of T cell memory against the same antigen induced by virus versus intracellular bacteria. Proc Natl Acad Sci U S A 1999; 96 (16): 9293-8
52. Haglund K, Leiner I, Kerksiek K, et al. Robust recall and long-term memory T-cell responses induced by prime-boost regimens with heterologous live viral vectors expressing human immunodeficiency virus type 1 Gag and Env proteins. J Virol 2002; 76 (15): 7506-17
53. Blattman JN, Grayson JM, Wherry EJ, et al. Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med 2003; 9: 540-7
54. Mitchell T, Hildeman D, Keoll R, et al. Immunological adjuvants promote activated T cell survival via induction of Bcl-3. Nat Immunol 2001; 2 (5): 397-402
55. Schluns KS, Lefrancois L. Cytokine control of memory T-cell development and survival. Nat Rev Immunol 2003; 3 (4): 269-79
56. Manz RA, Arce S, Cassese G, et al. Humoral immunity and long-lived plasma cells. Curr Opin Immunol 2002; 14 (4): 517-21
57. McHeyzer-Williams LJ, Driver DJ, McHeyzer-Williams MG. Germinal center reaction. Curr Opin Hematol 2001; 8 (1): 52-9
58. Calame KL, Lin KI, Tunyaplin C. Regulatory mechanisms that determine the development and function of plasma cells. Annu Rev Immunol 2003; 21: 205-30
59. Walker LS, Gulbranson-Judge A, Flynn S, et al. Co-stimulation and selection for T-cell help for germinal centres: the role of CD28 and OX40. Immunol Today 2000; 21 (7): 333-7
60. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002; 298: 2199-202
61. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol 2003; 3 (3): 253-7
62. Francois BJ. Regulatory T cells under scrutiny. Nat Rev Immunol 2003; 3 (3): 189-98
63. McGuirk P, Mills KH. Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol 2002; 23 (9): 450-5
64. Belkaid Y, Piccirillo CA, Mendez S, et al. CD4+CD25+ regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420 (6915): 502-7
65. Piccirillo CA, Shevach EM. Cutting edge: control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001; 167 (3): 1137-40
66. Lundgren A, Suri-Payer E, Enarsson K, et al. Helicobacter pylori-specific CD4 (+) CD25 (high) regulatory T cells suppress memory T-cell responses to H. pylori in infected individuals. Infect Immun 2003; 71 (4): 1755-62
67. McGuirk P, McCann C, Mills KH. Pathogen-specific T regulatory 1 cells induced in the respiratory tract by a bacterial molecule that stimulates interleukin 10 production by dendritic cells: a novel strategy for evasion of protective T helper type 1 responses by Bordetella pertussis. J Exp Med 2002; 195 (2): 221-31
68. Boussiotis VA, Tsai EY, Yunis EJ, et al. IL-10-producing T cells suppress immune responses in anergic tuberculosis patients. J Clin Invest 2000; 105 (9): 1317-25
69. Jonuleit H, Schmitt E, Steinbrink K, et al. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol 2001; 22 (7): 394-400
70. Akbari O, Freeman GJ, Meyer EH, et al. Antigen-specific regulatory T cells develop via the ICOS-ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity. Nat Med 2002; 8 (9): 1024-32
71. Sakaguchi S. Control of immune responses by naturally arising CD4+ regulatory T cells that express toll-like receptors. J Exp Med 2003; 197 (4): 397-401
72. Caramalho I, Lopes-Carvalho T, Ostler D, et al. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003; 197 (4): 403-11
73. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression by dendritic cells. Science 2003; 299 (5609): 1033-6
74. Walker RI. New strategies for using mucosal vaccination to achieve more effective immunisation. Vaccine 1994; 12: 87-93
75. Hathaway LJ, Kraehenbuhl JP. The role of M cells in mucosal immunity. Cell Mol Life Sci 2000; 57 (2): 323-32
76. Jump RL, Levine AD. Murine Peyer's patches favor development of an IL-10-secreting, regulatory T cell population. J Immunol 2002; 168 (12): 6113-9
77. Alpan O, Rudomen G, Matzinger P. The role of dendritic cells, B cells, and M cells in gut-oriented immune responses. J Immunol 2001; 166 (8): 4843-52
78. Shreedhar VK, Kelsall BL, Neutra MR. Cholera toxin induces migration of dendritic cells from the subepithelial dome region to T-and B-cell areas of Peyer's patches. Infect Immun 2003; 71 (1): 504-9
79. Zhou F, Kraehenbuhl JP, Neutra M. Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes. Vaccine 1995; 13: 637-44
80. Eldridge JH, Staas JK, Meulbroek JA, et al. Biodegradable microspheres as a vaccine delivery system. Mol Immunol 1991; 28: 287-94
81. Lambert JS, Keefer M, Mulligan MJ, et al. A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. Vaccine 2001; 19 (23-24): 3033-42
82. Katz DE, DeLorimier AJ, Wolf MK, et al. Oral immunization of adult volunteers with microencapsulated enterotoxigenic Escherichia coli (ETEC) CS6 antigen. Vaccine 2003; 21 (5-6): 341-6
83. Clark MA, Blair H, Liang L, et al. Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine 2001; 20 (1-2): 208-17
84. Wu Y, Wang X, Csencsits KL, et al. M cell-targeted DNA vaccination. Proc Natl Acad Sci U S A 2001; 98 (16): 9318-23
85. Lavelle EC, Grant G, Pusztai A, et al. Mucosal immunogenicity of plant lectins in mice. Immunology 2000; 99 (1): 30-7
86. Nardelli-Haefliger D, Kraehenbuhl JP, Curtis III R, et al. Oral and rectal immunisation of adult female volunteers with a recombinant attenuated Salmonella typhi vaccine strain. Infect Immun 1996; 64: 5219-25
87. Sizemore DR, Branstrom AA, Sadoff JC. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunisation. Science 1995; 270: 299-302
88. DiPetrillo MD, Tibbetts T, Kleanthous H, et al. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999; 18 (5-6): 449-59
89. De Geus B, Dol-Bosman M, Scholten JW, et al. A comparison of natural and recombinant cholera toxin B subunit as stimulatory factors in intranasal immunisation. Vaccine 1997; 15: 1110-8
90. Rappuoli R, Pizza M, Douce G, et al. Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins. Immunol Today 1999; 20 (11): 493-500
91. Baudner BC, Balland O, Giuliani MM, et al. Enhancement of protective efficacy following intranasal immunization with vaccine plus a nontoxic LTK63 mutant delivered with nanoparticles. Infect Immun 2002; 70 (9): 4785-90
92. van Ginkel FW, Jackson RJ, Yuki Y, et al. The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000; 165 (9): 4778-82
93. Hagiwara Y, Iwasaki T, Asanuma H, et al. Effects of intranasal administration of cholera toxin (or Escherichia coli heat-labile enterotoxin) B subunits supplemented with a trace amount of the holotoxin on the brain. Vaccine 2001; 19 (13-14): 1652-60
94. Hodge LM, Marinaro M, Jones HP, et al. Immunoglobulin A (IgA) responses and IgE-associated inflammation along the respiratory tract after mucosal but not systemic immunization. Infect Immun 2001; 69 (4): 2328-38
95. Sun JB, Holmgren J, Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci U S A 1994; 91: 10795-800
96. McSorley S, Rask C, Pichot R, et al. Selective tolerization of Th1 like cells after nasal administration of a cholera toxoid-LACK antigen. Eur J Immunol 1998; 28: 424-30
97. Lillard Jr JW, Boyaka PN, Taub D, et al. RANTES potentiates antigen-specific mucosal immune responses. J Immunol 2001; 166 (1): 162-9
98. Staats HF, Ennis Jr FA. IL-1 is an effective adjuvant for mucosal and systemic immune responses when coadministered with protein immunogens. J Immunol 1999 May 15; 162 (10): 6141-7
99. McCluskie MJ, Weeratna RD, Payette PJ, et al. The potential of CpG oligodeoxynucleotides as mucosal adjuvants. Crit Rev Immunol 2001; 21 (1-3): 103-20
100. Csencsits KL, Jutila MA, Pascual DW. Mucosal addressin expression and binding-interactions with naive lymphocytes vary among the cranial, oral, and nasal-associated lymphoid tissues. Eur J Immunol 2002; 32 (11): 3029-39